Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Inhibitor Therapeutics, Inc. (INTI) had Income from Continuous Operations of $-3.34M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-3.34M |
|
-- |
|
-- |
|
$3.66M |
|
$-3.66M |
|
$0.32M |
|
$-3.34M |
|
$-3.34M |
|
$-3.34M |
|
|
Income from Continuous Operations |
$-3.34M |
$-3.34M |
|
$-3.34M |
|
$-3.66M |
|
$-3.66M |
|
172.26M |
|
172.26M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$5.69M |
|
-- |
|
-- |
|
$5.69M |
|
$0.71M |
|
-- |
|
$3.00M |
|
$3.71M |
|
$1.99M |
|
$1.99M |
|
$1.99M |
|
172.32M |
|
| Cash Flow Statement Financials | |
$-3.23M |
|
-- |
|
-- |
|
$8.84M |
|
$5.61M |
|
$-3.23M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-168.22% |
|
-168.22% |
|
-58.64% |
|
-168.22% |
|
$0.01 |
|
$-0.02 |
|
$-0.02 |
|